Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

← catalyst calendar

NCT05338970

Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
586actual
Sites
182
Countries
Australia, Austria, Belgium +18

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-07-08actualWhen the study began enrolling
Primary completion2024-05-31actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-06-30estimatedThe whole study's end, after follow-up
First posted2022-04-21actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-01-31actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Nonsquamous Non-small Cell Lung Cancer
  • EGFR L858R
  • EGFR Exon 19 Deletion

Interventions

  • Drug: Patritumab Deruxtecan — also filed as HER3-DXd, U3-1402
  • Drug: Platinum-based chemotherapy

Primary outcome

what the primary-completion date above is the date OF
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1
measured Baseline up to approximately 49 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed